In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. Comprehensive and cutting-edge, Cardiac Markers, Second Edition offers physicians a complete guide to the use of cardiac markers in clinical practice and clinical laboratorians a close-up view of the new markers now becoming standard.

Foreword

viii

Preface

xi

Contributors

xv

PART I. CARDIAC MARKERS IN CLINICAL PRACTICE

l Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Protocols

Andra L. Blomkalns and W. Brian Gibler

3

(12)

2 Management of Acute Coronary Syndromes

Constantine N. Aroney and James A. de Lemos

15

(22)

3 Evolution of Cardiac Markers in Clinical Trials

Alexander S. Ro and Christopher R. de Filippi

37

(22)

4 Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise

Robert H. Christensen and Hassan M. E. Azzazy

59

(28)

5 The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents

Eugene H. Herman, Steven E. Lipshultz, and Victor J. Ferraris

87

(24)

6 The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery

Jesse E. Adams, III

111

(14)

PART II. CLINICAL USE FOR CARDIAC TROPONINS

7 Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications

Ralf Labugger, D. Kent Arrell, and Jennifer E. Van Eyk

125

(14)

8 Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients

Fred S. Apple

139

(10)

9 Cardiac-Specific Troponins Beyond Ischemic Heart Disease

David Morrow

149

(24)

PART III. ANALYTICAL ISSUES FOR CARDIAC MARKERS

10 Antibody Selection Strategies in Cardiac Troponin Assays

Alexei Katrukha

173

(14)

11 Interferences in Immunoassays for Cardiac Troponin

Kiang-Teck J. Yeo and Daniel M. Hoefner

187

(12)

12 Cardiac Marker Measurement by Point-of-Care Testing

Paul 0. Collinson

199

(14)

13 Standardization of Cardiac Markers

Mauro Panteghini

213

(18)

14 Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers

Alan H. B. Wu

231

(14)

PART IV. EARLY CARDIAC MARKERS OF MYOCARDIAL ISCHEMIA AND RISK STRATIFICATION

15 Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes

Robert L. Jesse

245

(14)

16 Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin

Alan H. B. Wu, Peter Crosby, Gary Fagan, Oliver Danne, Ulrich Frei, Martin Möckel, and Joseph Keffer

259

(20)

17 C-Reactive Protein for Primary Risk Assessment

Gavin J. Blake and Paul M. Ridker

279

(12)

18 Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes

Luigi M. Biasucci, Antonio Abbate, and Giovanna Liuzzo

291

(14)

19 Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement

Thomas B. Ledue and Nader Rifai

305

(14)

20 Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification

Jan F. C. Glatz, Roy F. M. van der Putten, and Wim T. Hermens

319

(20)

21 Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein in Patients with Coronary Artery Disease

Paul Holvoet

339

(12)

PART V. CARDIAC MARKERS OF CONGESTIVE HEART FAILURE

22 Pathophysiology of Heart Failure

Johannes Mair

351

(18)

23 B-Type Natriuretic Peptide: Biochemistry and Measurement

Jeffrey R. Dahlen

369

(10)

24 B-Type Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure

Ramie Tabbibizar and Alan Maisel

379

(18)

25 Monitoring Efficacy of Treatment with Brain Natriuretic Peptide

Emil D. Missov and Leslie W. Miller

397

(14)

26 N-Terminal Pro-B-Type Natriuretic Peptide

Torbjorn Omland and Christian Hall

411

(16)

PART VI. ROLE OF INFECTIOUS DISEASES AND GENETICS IN HEART DISEASE

27 Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae

Martin Möckel

427

(12)

28 Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics

Alan H. B. Wu

439

(22)

Index

461

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.